Securities code: 300636 securities abbreviation: Jiangxi Synergy Pharmaceutical Co.Ltd(300636) Announcement No.: 2022-002 bond Code: 123073 bond abbreviation: Tonghe convertible bond
Jiangxi Synergy Pharmaceutical Co.Ltd(300636)
Announcement of resolutions of the fourth meeting of the third board of directors
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
1、 Convening of board meeting
The fourth meeting of the third board of directors (hereinafter referred to as the “meeting”) of Jiangxi Synergy Pharmaceutical Co.Ltd(300636) (hereinafter referred to as “the company”) was notified by telephone and e-mail on January 6, 2022. It was held in the company’s conference room by on-site combined with communication voting on January 11, 2022. The meeting should be attended by 9 directors, 9 directors actually present (including 2 directors (Liang Zhongcheng and Li Guoping) voting by means of communication). The meeting was presided over by Mr. Pang Zhengwei, chairman of the board of directors, and the supervisors and senior executives of the company attended the meeting as nonvoting delegates. The convening, convening and voting procedures of this meeting comply with the company law of the people’s Republic of China and other relevant laws and regulations and the articles of association, and the meeting is legal and effective.
2、 Deliberations of the board meeting
After careful consideration by the directors present, the following resolutions were adopted by open ballot:
1. The proposal on adjusting the implementation progress of the company’s investment projects with raised funds was deliberated and adopted
It is agreed that the company will adjust the implementation progress of the “phase I project of the project with an annual output of 100 tons of 7-methoxynaphthone, 30 tons of rivaroxaban and 2 billion tablets (tablets) of oral solid preparations”, adjust the start time of trial production from December 2021 to August 2022, and adjust the formal production time from December 2022 to August 2023.
For details, please refer to cninfo.com, the gem information disclosure website designated by CSRC（ http://www.cn.info.com.cn. ）Announcement on adjusting the implementation progress of the company’s investment projects with raised funds.
The independent directors of the company expressed their independent opinions on this matter. For details, see the company’s disclosure on the same day on the gem information disclosure website cninfo.com designated by the CSRC（ http://www.cn.info.com.cn. ）Independent opinions of Jiangxi Synergy Pharmaceutical Co.Ltd(300636) independent directors on relevant matters of the fourth meeting of the third board of directors of the company.
The recommendation institution China Merchants Securities Co.Ltd(600999) issued verification opinions on this proposal. For details, see the company’s disclosure on the same day on the gem information disclosure website designated by the CSRC（ http://www.cn.info.com.cn. ）The China Merchants Securities Co.Ltd(600999) verification opinions on Jiangxi Synergy Pharmaceutical Co.Ltd(300636) adjusting the implementation progress of the company’s investment projects with raised funds.
Voting results: 9 in favor, 0 against and 0 abstention.
This proposal will come into force after being deliberated and approved by the board of directors, and does not need to be submitted to the general meeting of shareholders for deliberation and approval. 2. The proposal on the implementation of new, modified and expanded projects of some workshops and devices in the second plant area of the company was reviewed and approved
It is agreed that the company will implement the new, reconstruction and expansion projects of some workshops and devices in plant area 2 based on the phase I project of plant area 2, mainly including the construction and reconstruction of some solvent tank farms, utilities and the expansion and reconstruction of some workshops. The project is planned to start construction in 2022, with a total construction period of 4 years and a total investment of 1415.6075 million yuan, including 1223.8887 million yuan of construction investment, 146 million yuan of initial working capital and 45.7188 million yuan of interest during the construction period.
Voting results: 9 in favor, 0 against and 0 abstention.
This proposal needs to be submitted to the first extraordinary general meeting of shareholders of the company in 2022 for deliberation.
3. The proposal on convening the first extraordinary general meeting of shareholders in 2022 was deliberated and adopted
For details, please refer to cninfo.com, the gem information disclosure website designated by CSRC（ http://www.cn.info.com.cn. ）Notice on convening the first extraordinary general meeting of shareholders in 2022.
Voting results: 9 in favor, 0 against and 0 abstention.
3、 Documents for future reference
1. Resolutions of the fourth meeting of the third board of directors of the company;
2. Independent opinions of independent directors on matters related to the fourth meeting of the third board of directors of the company.
It is hereby announced.
Jiangxi Synergy Pharmaceutical Co.Ltd(300636) board of directors January 11, 2002
